title: Comprehensive lung injury pathology induced by mTOR inhibitors.
abstract: Interstitial lung disease is a rare side effect of temsirolimus treatment in renal cancer patients. Pulmonary fibrosis is characterised by the accumulation of extracellular matrix collagen, fibroblast proliferation and migration, and loss of alveolar gas exchange units. Previous studies of pulmonary fibrosis have mainly focused on the fibroproliferative process in the lungs. However, the molecular mechanism by which sirolimus promotes lung fibrosis remains elusive. Here, we propose an overall cascade hypothesis of interstitial lung diseases that represents a common, partly underlying synergism among them as well as the lung pathogenesis side effects of mammalian target of rapamycin inhibitors.
authors: Oncology Research Lab, INIBIC, A Coruña, Spain.
authors: Guadalupe
authors: G
authors: Aparicio
authors: Moisés B
authors: MB
authors: Calvo
authors: Vanessa
authors: V
authors: Medina
authors: Ovidio
authors: O
authors: Fernández
authors: Paula
authors: P
authors: Jiménez
authors: Martina
authors: M
authors: Lema
authors: Angélica
authors: A
authors: Figueroa
authors: Luis M
authors: LM
authors: Antón Aparicio
mesh_terms: D006801:Humans; D008168:Lung / Q000473:pathology*; D055370:Lung Injury / Q000139:chemically induced*; D008954:Models, Biological; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011494:Protein Kinases / Q000378:metabolism*; D011658:Pulmonary Fibrosis / Q000139:chemically induced*; D017382:Reactive Oxygen Species / Q000378:metabolism; D058570:TOR Serine-Threonine Kinases
chemical_list: D047428:Protein Kinase Inhibitors; D017382:Reactive Oxygen Species; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases